1
|
Cook JD, Gratton MKP, Bender AM, Werthner P, Lawson D, Pedlar CR, Kipps C, Bastien CH, Samuels CH, Charest J. Sleep Health, Individual Characteristics, Lifestyle Factors, and Marathon Completion Time in Marathon Runners: A Retrospective Investigation of the 2016 London Marathon. Brain Sci 2023; 13:1346. [PMID: 37759947 PMCID: PMC10527296 DOI: 10.3390/brainsci13091346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 09/08/2023] [Accepted: 09/18/2023] [Indexed: 09/29/2023] Open
Abstract
Despite sleep health being critically important for athlete performance and well-being, sleep health in marathoners is understudied. This foundational study explored relations between sleep health, individual characteristics, lifestyle factors, and marathon completion time. Data were obtained from the 2016 London Marathon participants. Participants completed the Athlete Sleep Screening Questionnaire (ASSQ) along with a brief survey capturing individual characteristics and lifestyle factors. Sleep health focused on the ASSQ sleep difficulty score (SDS) and its components. Linear regression computed relations among sleep, individual, lifestyle, and marathon variables. The analytic sample (N = 943) was mostly male (64.5%) and young adults (66.5%). A total of 23.5% of the sample reported sleep difficulties (SDS ≥ 8) at a severity warranting follow-up with a trained sleep provider. Middle-aged adults generally reported significantly worse sleep health characteristics, relative to young adults, except young adults reported significantly longer sleep onset latency (SOL). Sleep tracker users reported worse sleep satisfaction. Pre-bedtime electronic device use was associated with longer SOL and longer marathon completion time, while increasing SOL was also associated with longer marathon completion. Our results suggest a deleterious influence of pre-bedtime electronic device use and sleep tracker use on sleep health in marathoners. Orthosomnia may be a relevant factor in the relationship between sleep tracking and sleep health for marathoners.
Collapse
Affiliation(s)
- Jesse D. Cook
- Department of Psychiatry, University of Wisconsin-Madison, Madison, WI 53706, USA
- Department of Psychology, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Matt K. P. Gratton
- Division of Medical Informatics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, MO 66160, USA;
- Social and Behavioral Sciences, Psychology, University of Kansas, Lawrence, KS 66045, USA
| | - Amy M. Bender
- Faculty of Kinesiology, University of Calgary, Calgary, AB T2N 1N4, Canada; (A.M.B.); (P.W.); (C.H.S.); (J.C.)
| | - Penny Werthner
- Faculty of Kinesiology, University of Calgary, Calgary, AB T2N 1N4, Canada; (A.M.B.); (P.W.); (C.H.S.); (J.C.)
| | - Doug Lawson
- Centre for Sleep and Human Performance, Calgary, AB T2X 3V4, Canada;
| | - Charles R. Pedlar
- Faculty of Sport, Allied Health, and Performance Science, Twickenham, St Mary’s University, London TW1 4SX, UK;
- Institute of Sport, Exercise and Health, University College London, London WC1E 6JB, UK;
| | - Courtney Kipps
- Institute of Sport, Exercise and Health, University College London, London WC1E 6JB, UK;
| | - Celyne H. Bastien
- École de Psychologie, Université Laval, Québec City, QC G1V 0A6, Canada;
| | - Charles H. Samuels
- Faculty of Kinesiology, University of Calgary, Calgary, AB T2N 1N4, Canada; (A.M.B.); (P.W.); (C.H.S.); (J.C.)
- Centre for Sleep and Human Performance, Calgary, AB T2X 3V4, Canada;
- Faculty of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
| | - Jonathan Charest
- Faculty of Kinesiology, University of Calgary, Calgary, AB T2N 1N4, Canada; (A.M.B.); (P.W.); (C.H.S.); (J.C.)
- Centre for Sleep and Human Performance, Calgary, AB T2X 3V4, Canada;
- École de Psychologie, Université Laval, Québec City, QC G1V 0A6, Canada;
| |
Collapse
|
2
|
Lawson D, Kang H, Degani A. Sleep quality after extreme muscle fatigue with active and placebo Transcutaneous Nerve Stimulation. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Lawson D, Degani AM, Lee K, Beer EI, Gohlke KE, Hamidi KN, Coler MA, Tews NM. The use of transcutaneous electrical nerve stimulation along with functional tasks for immediate pain relief in individuals with knee osteoarthritis. Eur J Pain 2021; 26:754-765. [PMID: 34964537 DOI: 10.1002/ejp.1903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Knee pain is the major complaint in individuals with knee osteoarthritis (OA), and the effects of transcutaneous electrical nerve stimulation (TENS) on knee pain are controversial. The present study applied TENS along with functional tests to investigate its effect on pain level in individuals with mild to moderate knee OA. METHODS Twenty volunteers with knee OA classification of graded 2-3 performed four functional tests (stair climb test - SCT, timed up and go test - TUG, 6-minute walk test - 6MWT, knee extensor strength test - KES, and 2-step test from the locomotive syndrome risk test - LSR_2ST) while wearing either an active or inactive TENS. Knee pain level before and after each test was self-accessed by the visual analog scale (VAS). The effect of TENS (active vs. inactive) on pain level was submitted to statistical analyses. RESULTS Knee pain during SCT, TUG, and LSR_2ST tests was significantly lower when subjects used the active TENS, compared to using the inactive unit. The effect of the active TENS on pain level was also more significant in subjects with no anxiety or depression. CONCLUSIONS The results provided evidence of immediate pain relief in individuals with mild to moderate knee OA when TENS is applied along with functional activities, that usually induced pain in people with knee OA.
Collapse
Affiliation(s)
- D Lawson
- Laboratory for Advancements in Rehabilitation Sciences (LARS), Department of Physical Therapy, Western Michigan University, Kalamazoo, MI, USA
| | - A M Degani
- Laboratory for Advancements in Rehabilitation Sciences (LARS), Department of Physical Therapy, Western Michigan University, Kalamazoo, MI, USA
| | - K Lee
- Department of Statistics, Western Michigan University, Kalamazoo, MI, USA
| | - E I Beer
- College of Health Services and Sciences, Western Michigan University, Kalamazoo, MI, USA
| | - K E Gohlke
- Department of Physical Therapy, Western Michigan University, Kalamazoo, MI, USA
| | - K N Hamidi
- Department of Physical Therapy, Western Michigan University, Kalamazoo, MI, USA
| | - M A Coler
- Department of Physical Therapy, Western Michigan University, Kalamazoo, MI, USA
| | - N M Tews
- College of Health Services and Sciences, Western Michigan University, Kalamazoo, MI, USA.,College of Arts and Sciences, Western Michigan University, Kalamazoo, MI, USA
| |
Collapse
|
4
|
Charest J, Samuels CH, Bastien CH, Lawson D, Grandner MA. Impacts of travel distance and travel direction on back-to-back games in the National Basketball Association. J Clin Sleep Med 2021; 17:2269-2274. [PMID: 34170248 DOI: 10.5664/jcsm.9446] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
STUDY OBJECTIVES Travel fatigue and circadian disruptions are known factors that can hinder performance in professional athletes. The present study focused on travel distance and direction on back-to-back games over the 2013-2020 seasons in the National Basketball Association (NBA). METHODS The outcomes were based on winning percentage with additional covariates including the direction of travel (eastward or westward), the distance traveled (0-500 km; 501-1,000 km; 1,001-1,500 km; 1,501 km and more), team quality, and season. If a team played both games of a back-to-back sequence on the road, they were considered Away-Away; if a team played the first game of a back-to-back sequence at home they were considered Home-Away; if a team played the first game of a back-to-back sequence on the road they were considered Away-Home. RESULTS The sequence Away-Home significantly increases the likelihood of winning compared with the Away-Away and Home-Away sequences: 54.4% (95% confidence interval [CI], 54.4%-54.5%), 39.2% (95% CI, 37.2%-41.2%), and 36.8% (95% CI, 36.7%-36.8%), respectively. When teams travel back home, every additional 500 km reduces the likelihood of winning by approximately 4% (P = .038). Finally, after withdrawing the Away-Home sequence, traveling eastward significantly increases the chance of winning (P = .024) compared with westward travel but has no significant impact on the probability of winning compared with neutral time zone travel (P = .091). CONCLUSIONS The accumulation of travel fatigue and the chronic circadian desynchronization that occurs over the NBA season can acutely disturb sleep and recovery. It appears that tailored sleep and recovery strategies need to be dynamically developed throughout the season to overcome the different challenges of the NBA schedule. CITATION Charest J, Samuels CH, Bastien CH, Lawson D, Grandner MA. Impacts of travel distance and travel direction on back-to-back games in the National Basketball Association. J Clin Sleep Med. 2021;17(11):2269-2274.
Collapse
Affiliation(s)
- Jonathan Charest
- Department of Psychology, University Laval, Québec City, Québec, Canada.,Centre for Sleep and Human Performance, Calgary, Alberta, Canada
| | - Charles H Samuels
- Centre for Sleep and Human Performance, Calgary, Alberta, Canada.,Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | | | - Doug Lawson
- Centre for Sleep and Human Performance, Calgary, Alberta, Canada
| | | |
Collapse
|
5
|
Charest J, Samuels C, Bastien C, Lawson D, Grandner M. 295 Impacts of travel distance and travel direction on back-to-back games in the National Basketball Association (NBA). Sleep 2021. [DOI: 10.1093/sleep/zsab072.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Travel fatigue and circadian disruptions are known factors that can hinder performance in professional athletes. The present exploratory study focused on investigating the impact of travel distance and direction on back-to-back games over the 2013–2020 seasons in the National Basketball Association (NBA).
Methods
Data from away and home games of back-to-back sequences, in two different cities, from the 2013 to 2020 seasons in the National Basketball Association were included in this study. Information from every selected game was retrieved from the official website of the NBA (www.nba.com). The outcomes were based on winning percentage with additional covariates including the direction of travel (eastward or westward) and the distance travelled (0-500km – 501-1000km – 1001-1500km – 1501km and more). If a team played both games of a back-to-back sequence on the road, they were considered Away-Away; if a team played the first game of a back-to-back sequence at home they were considered Home-Away; if a team played the first game of a back-to-back sequence on the road they were considered Away-Home.
Results
The sequence Away-Home significantly increases the likelihood of winning compared to the Away-Away and Home-Away sequences 54.4% (95%CI: 54.4,54.5); 39.2% (95%CI: 37.2,41.2), and 36.8%, (95%CI: 36.7,36.8), respectively. Following a road game, when teams travel back home, every additional 500km reduces the likelihood of winning by approximately 4% (p = 0.038). Finally, after withdrawing the Away-Home sequence, travelling eastward significantly increases the chance of winning (p = 0.024) compared to westward travel but has no significant impact on the probability of winning compared to neutral time zone travel (p = 0.091).
Conclusion
The accumulation of travel fatigue and the chronic circadian desynchronization that occurs over the NBA season can acutely disturb sleep and recovery. It appears that tailored sleep and recovery strategies need to be dynamically developed throughout the season to overcome the different challenges of the NBA schedule.
Support (if any):
Collapse
|
6
|
Charest J, Samuels C, Bastien C, Lawson D, Grandner M. 294 Impacts of travel and time zone differences in the National Hockey League (NHL). Sleep 2021. [DOI: 10.1093/sleep/zsab072.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Elite athletes are at risk of poor sleep which can be exacerbated by frequent travel. The present exploratory study investigated the impact of travel on the winning percentage, number of goals scored in the 3rd period and the number of penalties in the 3rd period over the 2013–2020 seasons in the National Hockey League (NHL).
Methods
Data from away and home games from the 2013–2020 seasons in the NHL were included in this study. The outcomes were based on winning percentage with additional covariates including home and away games; timing of the game (afternoon/17:30 or earlier; evening/18:00 or later; number of time zones travelled (one, two or three); direction of the travel (eastward or westward); length of the game (regular, overtime or shootout). Additionally, data exclusively from the 3rd period were assessed for the number of penalties received and the number of goals scored for and against. Data were analyzed with logistic regressions to evaluate the effects of the aforementioned variables on winning percentage for both eastern and western conference teams.
Results
Regardless of the length of the game, results indicated no difference between eastern and western teams on winning percentage. However, there was a significant impact of home-ice on winning percentage for both conferences (p<0.001). In addition, there was no difference on the winning percentage based on the travel direction and the number of time zones crossed (p = 0.747) or the time of the day (p=0.991). Moreover, visiting teams received significantly more 3rd period penalties than home teams (p<0.001), regardless of travel and while travelling within the same time zone compared to eastward travel (p<0.001) but not westward travel (p=0.078). Finally, there was an increased risk of being scored against when team travelled three time zones (p=0.03), regardless of the direction.
Conclusion
This 7-year investigation of data from the NHL demonstrates an unexplored aspect of the impact that travel and circadian factors may have on emotion regulation and performance. Translational application of this knowledge to enhance general public health and performance would be warranted.
Support (if any):
Collapse
|
7
|
Green BN, Johnson CD, Brown R, Korporaal C, Lawson D, Russell E, Fujikawa R. An international stakeholder survey of the role of chiropractic qualifying examinations: A qualitative analysis. J Chiropr Educ 2020; 34:15-30. [PMID: 31928424 PMCID: PMC7074948 DOI: 10.7899/jce-19-22] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
OBJECTIVE Many countries require examinations as a gateway to chiropractic licensure; however, the relevance of these exams to the profession has not been explored. The purposes of this study were to analyze perceptions of international stakeholders about chiropractic qualifying examinations (CQEs), observe if their beliefs were in alignment with those that society expects of professions, and suggest how this information may be used when making future decisions about CQEs. METHODS We designed an electronic survey that included open-ended questions related to CQEs. In August 2019, the survey was distributed to 234 international stakeholders representing academic institutions, qualifying boards, students, practitioners, association officers, and others. Written comments were extracted, and concepts were categorized and collapsed into 4 categories (benefits, myths, concerns, solutions). Qualitative analysis was used to identify themes. RESULTS The response rate was 56.4% representing 43 countries and yielding 775 comments. Perceived benefits included that CQEs certify a minimum standard of knowledge and competency and are part of the professionalization of chiropractic. Myths included that CQEs are able to screen for future quality of care or ethical practices. Concerns included a lack of standardization between jurisdictions and uncertainty about the cost/value of CQEs and what they measure. Solutions included suggestions to standardize exams across jurisdictions and focus on competencies. CONCLUSION International stakeholders identified concepts about CQEs that may facilitate or hinder collaboration and efforts toward portability. Stakeholder beliefs were aligned with those expected of learned professions. This qualitative analysis identified 9 major themes that may be used when making future decisions about CQEs.
Collapse
|
8
|
Buchwald Z, Nasti T, Wieland A, Hudson W, Valanparambil R, Eberhardt C, Lawson D, Lin J, Curran W, Ahmed R, Khan M. The Effect of Dexamethasone on the Αpd-1/L1 and Radiotherapy Stimulated Anti-Tumor Response. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Levey A, Elsayed M, Lawson D, Ermentrout R, Kudchadkar R, Bercu Z, Yushak M, Newsome J, Kokabi N. 03:18 PM Abstract No. 230 Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization: a 15-year single-institution experience. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.289] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Bender AM, Lawson D, Werthner P, Samuels CH. The Clinical Validation of the Athlete Sleep Screening Questionnaire: an Instrument to Identify Athletes that Need Further Sleep Assessment. Sports Med Open 2018; 4:23. [PMID: 29869021 PMCID: PMC5986689 DOI: 10.1186/s40798-018-0140-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Accepted: 05/24/2018] [Indexed: 11/18/2022]
Abstract
Background Previous research has established that general sleep screening questionnaires are not valid and reliable in an athlete population. The Athlete Sleep Screening Questionnaire (ASSQ) was developed to address this need. While the initial validation of the ASSQ has been established, the clinical validity of the ASSQ has yet to be determined. The main objective of the current study was to evaluate the clinical validity of the ASSQ. Methods Canadian National Team athletes (N = 199; mean age 24.0 ± 4.2 years, 62% females; from 23 sports) completed the ASSQ. A subset of athletes (N = 46) were randomized to the clinical validation sub-study which required subjects to complete an ASSQ at times 2 and 3 and to have a clinical sleep interview by a sleep medicine physician (SMP) who rated each subjects’ category of clinical sleep problem and provided recommendations to improve sleep. To assess clinical validity, the SMP category of clinical sleep problem was compared to the ASSQ. Results The internal consistency (Cronbach’s alpha = 0.74) and test-retest reliability (r = 0.86) of the ASSQ were acceptable. The ASSQ demonstrated good agreement with the SMP (Cohen’s kappa = 0.84) which yielded a diagnostic sensitivity of 81%, specificity of 93%, positive predictive value of 87%, and negative predictive value of 90%. There were 25.1% of athletes identified to have clinically relevant sleep disturbances that required further clinical sleep assessment. Sleep improved from time 1 at baseline to after the recommendations at time 3. Conclusions Sleep screening athletes with the ASSQ provides a method of accurately determining which athletes would benefit from preventative measures and which athletes suffer from clinically significant sleep problems. The process of sleep screening athletes and providing recommendations improves sleep and offers a clinical intervention output that is simple and efficient for teams and athletes to implement. Electronic supplementary material The online version of this article (10.1186/s40798-018-0140-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Amy M Bender
- Centre for Sleep & Human Performance, 106-51 Sunpark Dr. SE, Calgary, AB, T2X 3V4, Canada. .,Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.
| | - Doug Lawson
- Centre for Sleep & Human Performance, 106-51 Sunpark Dr. SE, Calgary, AB, T2X 3V4, Canada.,Faculty of Chiropractic, D'Youville College, Buffalo, NY, USA
| | - Penny Werthner
- Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada
| | - Charles H Samuels
- Centre for Sleep & Human Performance, 106-51 Sunpark Dr. SE, Calgary, AB, T2X 3V4, Canada.,Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
11
|
Diop S, Kaly J, Lawson D, Diop M, Diop B. Connaissances, attitudes et pratiques des mères ou gardiennes d’enfants sur la chimioprévention du paludisme saisonnier. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Passalent L, Kang R, Lawson D, Hawke C, Omar A, Haroon N, Inman R. THU0644-HPR E-Learning: An Effective Method To Improve Disease Knowledge and Self-Efficacy for Patients with Axial Spondyloarthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Samuels C, James L, Lawson D, Meeuwisse W. The Athlete Sleep Screening Questionnaire: a new tool for assessing and managing sleep in elite athletes. Br J Sports Med 2015; 50:418-22. [DOI: 10.1136/bjsports-2014-094332] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/02/2015] [Indexed: 11/03/2022]
|
14
|
McCoon P, Woessner R, DuPont R, Bell K, Collins M, Pablo L, Lawson D, Nadella P, Jacobs V, Womack C, Reimer C, Hong D, Nemunaitis J, Kang Y, Kim T, Lim H, Okusaka T, Nadano S, Lin C, Lyne P. 501 Immunological STAT3 knockdown associated with anti-tumor activity in pre-clinical models translates to clinical samples, suggesting immune modulation contributes to the clinical activity of AZD9150, a therapeutic STAT3 ASO. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70627-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Bires AM, Lawson D, Wasser TE, Raber-Baer D. Comparison of Bruce Treadmill Exercise Test Protocols: Is Ramped Bruce Equal or Superior to Standard Bruce in Producing Clinically Valid Studies for Patients Presenting for Evaluation of Cardiac Ischemia or Arrhythmia with Body Mass Index Equal to or Greater Than 30? J Nucl Med Technol 2013; 41:274-8. [DOI: 10.2967/jnmt.113.124727] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Charlesworth SM, Nnadi E, Oyelola O, Bennett J, Warwick F, Jackson R, Lawson D. Laboratory based experiments to assess the use of green and food based compost to improve water quality in a Sustainable Drainage (SUDS) device such as a swale. Sci Total Environ 2012; 424:337-343. [PMID: 22449416 DOI: 10.1016/j.scitotenv.2012.02.075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Revised: 02/24/2012] [Accepted: 02/24/2012] [Indexed: 05/31/2023]
Abstract
Many tonnes of compost are generated per year due to door step composting of both garden and kitchen waste. Whilst there are commercial outlets for the finer grade of compost (<10mm) in plant nurseries, there is little demand for the coarser material (>25 mm). This paper reports part of a WRAP-sponsored (Waste Resources Action Programme) study which investigated the potential for green (GC) and mixed green and food (MC) composts to be incorporated into Sustainable Drainage (SUDS) devices such as swales, and replace the topsoil (TS) onto which turf is laid or grass seed distributed. However, it is not known whether compost can replace TS in terms of pollutant remediation, both the trapping of polluted particulates and in dealing with hydrocarbons such as oil, but also from a biofilm development and activity perspective. Using laboratory based experiments utilising leaching columns and an investigation of microbiological development in the composts studied, it was found that many of the differences in performance between MC and GC were insignificant, whilst both composts performed better in terms of pollutant retention than TS. Mixed compost in particular could be used in devices where there may be oil spillages, such as the lorry park of a Motorway Service Area due to its efficiency in degrading oil. Samples of GC and MC were found to contain many of the bacteria and fungi necessary for an active and efficient biofilm which would be an argument in their favour for replacement of TS and incorporation in swales.
Collapse
Affiliation(s)
- S M Charlesworth
- SUDS Applied Research Group, Coventry University, Priory Street, Coventry CV1 5LW, UK.
| | | | | | | | | | | | | |
Collapse
|
17
|
Fallows R, McCoy K, Hertza J, Klosson E, Estes B, Stroescu I, Salinas C, Stringer A, Aronson S, MacAllister W, Spurgin A, Morriss M, Glasier P, Stavinoha P, Houshyarnejad A, Jacobus J, Norman M, Peery S, Mattingly M, Pennuto T, Anderson-Hanley C, Miele A, Dunnam M, Edwards M, O'Bryant S, Johnson L, Barber R, Inscore A, Kegel J, Kozlovsky A, Tarantino B, Goldberg A, Herrera-Pino J, Jubiz-Bassi N, Rashid K, Noniyeva Y, Vo K, Stephens V, Gomez R, Sanders C, Kovacs M, Walton B, Schmitter-Edgecombe M, Schmitter-Edgecombe M, Parsey C, Cook D, Woods S, Weinborn M, Velnoweth A, Rooney A, Bucks R, Adalio C, White S, Blair J, Barber B, Marcy S, Barber B, Marcy S, Boseck J, McCormick C, Davis A, Berry K, Koehn E, Tiberi N, Gelder B, Brooks B, Sherman E, Garcia M, Robillard R, Gunner J, Miele A, Lynch J, McCaffrey R, Hamilton J, Froming K, Nemeth D, Steger A, Lebby P, Harrison J, Mounoutoua A, Preiss J, Brimager A, Gates E, Chang J, Cisneros H, Long J, Petrauskas V, Casey J, Picard E, Long J, Petrauskas V, Casey J, Picard E, Miele A, Gunner J, Lynch J, McCaffrey R, Rodriguez M, Fonseca F, Golden C, Davis J, Wall J, DeRight J, Jorgensen R, Lewandowski L, Ortigue S, Etherton J, Axelrod B, Green C, Snead H, Semrud-Clikeman M, Kirk J, Connery A, Kirkwood M, Hanson ML, Fazio R, Denney R, Myers W, McGuire A, Tree H, Waldron-Perrine B, Goldenring Fine J, Spencer R, Pangilinan P, Bieliauskas L, Na S, Waldron-Perrine B, Tree H, Spencer R, Pangilinan P, Bieliauskas L, Peck C, Bledsoe J, Schroeder R, Boatwright B, Heinrichs R, Baade L, Rohling M, Hill B, Ploetz D, Womble M, Shenesey J, Schroeder R, Semrud-Clikeman M, Baade L, VonDran E, Webster B, Brockman C, Burgess A, Heinrichs R, Schroeder R, Baade L, VonDran E, Webster B, Goldenring Fine J, Brockman C, Heinrichs R, Schroeder R, Baade L, VonDran E, Webster B, Brockman C, Heinrichs R, Schroeder R, Baade L, Bledsoe J, VonDran E, Webster B, Brockman C, Heinrichs R, Schroeder R, Baade L, VonDran E, Webster B, Brockman C, Heinrichs R, Thaler N, Strauss G, White T, Gold J, Tree H, Waldron-Perrine B, Spencer R, McGuire A, Na S, Pangilinan P, Bieliauskas L, Allen D, Vincent A, Roebuck-Spencer T, Cooper D, Bowles A, Gilliland K, Watts A, Ahmed F, Miller L, Yon A, Gordon B, Bello D, Bennett T, Yon A, Gordon B, Bennett T, Wood N, Etcoff L, Thede L, Oraker J, Gibson F, Stanford L, Gray S, Vroman L, Semrud-Clikeman M, Taylor T, Seydel K, Bure-Reyes A, Stewart J, Tourgeman I, Demsky Y, Golden C, Burns W, Gray S, Burns K, Calderon C, Tourgeman I, Golden C, Neblina C, San Miguel Montes L, Allen D, Strutt A, Scott B, Strutt A, Scott B, Armstrong P, Booth C, Blackstone K, Moore D, Gouaux B, Ellis R, Atkinson J, Grant I, Brennan L, Schultheis M, Hurtig H, Weintraub D, Duda J, Moberg P, Chute D, Siderowf A, Brescian N, Gass C, Brewster R, King T, Morris R, Krawiecki N, Dinishak D, Richardson G, Estes B, Knight M, Hertza J, Fallows R, McCoy K, Garcia S, Strain G, Devlin M, Cohen R, Paul R, Crosby R, Mitchell J, Gunstad J, Hancock L, Bruce J, Roberg B, Lynch S, Hertza J, Klosson E, Varnadore E, Schiff W, Estes B, Hertza J, Varnadore E, Estes B, Kaufman R, Rinehardt E, Schoenberg M, Mattingly M, Rosado Y, Velamuri S, LeBlanc M, Pimental P, Lynch-Chee S, Broshek D, Lyons P, McKeever J, Morse C, Ang J, Leist T, Tracy J, Schultheis M, Morgan E, Woods S, Rooney A, Perry W, Grant I, Letendre S, Morse C, McKeever J, Schultheis M, Musso M, Jones G, Hill B, Proto D, Barker A, Gouvier W, Nersesova K, Drexler M, Cherkasova E, Sakamoto M, Marcotte T, Hilsabeck R, Perry W, Carlson M, Barakat F, Hassanein T, Shevchik K, McCaw W, Schrock B, Smith M, Moser D, Mills J, Epping E, Paulsen J, Somogie M, Bruce J, Bryan F, Buscher L, Tyrer J, Stabler A, Thelen J, Lovelace C, Spurgin A, Graves D, Greenberg B, Harder L, Szczebak M, Glisky M, Thelen J, Lynch S, Hancock L, Bruce J, Ukueberuwa D, Arnett P, Vahter L, Ennok M, Pall K, Gross-Paju K, Vargas G, Medaglia J, Chiaravalloti N, Zakrzewski C, Hillary F, Andrews A, Golden C, Belloni K, Nicewander J, Miller D, Johnson S, David Z, Weideman E, Lawson D, Currier E, Morton J, Robinson J, Musso M, Hill B, Barker A, Pella R, Jones G, Proto D, Gouvier W, Vertinski M, Allen D, Thaler N, Heisler D, Park B, Barney S, Kucukboyaci N, Girard H, Kemmotsu N, Cheng C, Kuperman J, McDonald C, Carroll C, Odland A, Miller L, Mittenberg W, Coalson D, Wahlstrom D, Raiford S, Holdnack J, Ennok M, Vahter L, Gardner E, Dasher N, Fowler B, Vik P, Grajewski M, Lamar M, Penney D, Davis R, Korthauer L, Libon D, Kumar A, Holdnack J, Iverson G, Chelune G, Hunter C, Zimmerman E, Klein R, Prathiba N, Hopewell A, Cooper D, Kennedy J, Long M, Moses J, Lutz J, Tiberi N, Dean R, Miller J, Axelrod B, Van Dyke S, Rapport L, Schutte C, Hanks R, Pella R, Fallows R, McCoy K, O'Rourke J, Hilsabeck R, Petrauskas V, Bowden S, Romero R, Hulkonen R, Boivin M, Bangirana P, John C, Shapiro E, Slonaker A, Pass L, Smigielski J, Biernacka J, Geske J, Hall-Flavin D, Loukianova L, Schneekloth T, Abulseoud O, Mrazek D, Karpyak V, Terranova J, Safko E, Heisler D, Thaler N, Allen D, Van Dyke S, Axelrod B, Zink D, Puente A, Ames H, LePage J, Carroll C, Knee K, Mittenberg W, Cummings T, Webbe F, Shepherd E, Marcinak J, Diaz-Santos M, Seichepine D, Sullivan K, Neargarder S, Cronin-Golomb A, Franchow E, Suchy Y, Kraybill M, Holland A, Newton S, Hinson D, Smith A, Coe M, Carmona J, Harrison D, Hyer L, Atkinson M, Dalibwala J, Yeager C, Hyer L, Scott C, Atkinson M, Yeager C, Jacobson K, Olson K, Pella R, Fallows R, McCoy K, O'Rourke J, Hilsabeck R, Rosado Y, Kaufman R, Velamuri S, Rinehardt E, Mattingly M, Sartori A, Clay O, Ovalle F, Rothman R, Crowe M, Schmid A, Horne L, Horn G, Johnson-Markve B, Gorman P, Stewart J, Bure-Reyes A, Golden C, Tam J, McAlister C, Schmitter-Edgecombe M, Wagner M, Brenner L, Walker A, Armstrong L, Inman E, Grimmett J, Gray S, Cornelius A, Hertza J, Klosson E, Varnadore E, Schiff W, Estes B, Johnson L, Willingham M, Restrepo L, Bolanos J, Patel F, Golden C, Rice J, Dougherty M, Golden C, Sharma V, Martin P, Golden C, Bradley E, Dinishak D, Lockwood C, Poole J, Brickell T, Lange R, French L, Chao L, Klein S, Dunnam M, Miele A, Warner G, Donnelly K, Donnelly J, Kittleson J, Bradshaw C, Alt M, England D, Denney R, Meyers J, Evans J, Lynch-Chee S, Kennedy C, Moore J, Fedor A, Spitznagel M, Gunstad J, Ferland M, Guerrero NK, Davidson P, Collins B, Marshall S, Herrera-Pino J, Samper G, Ibarra S, Parrott D, Steffen F, Backhaus S, Karver C, Wade S, Taylor H, Brown T, Kirkwood M, Stancin T, Krishnan K, Culver C, Arenivas A, Bosworth C, Shokri-Kojori E, Diaz-Arrastia R, Marquez de la PC, Lange R, Ivins B, Marshall K, Schwab K, Parkinson G, Iverson G, Bhagwat A, French L, Lichtenstein J, Adams-Deutsch Z, Fleischer J, Goldberg K, Lichtenstein J, Adams-Deutsch Z, Fleischer J, Goldberg K, Lichtenstein J, Fleischer J, Goldberg K, Lockwood C, Ehrler M, Hull A, Bradley E, Sullivan C, Poole J, Lockwood C, Sullivan C, Hull A, Bradley E, Ehrler M, Poole J, Marcinak J, Schuster D, Al-Khalil K, Webbe F, Myers A, Ireland S, Simco E, Carroll C, Mittenberg W, Palmer E, Poole J, Bradley E, Dinishak D, Piecora K, Marcinak J, Al-Khalil K, Mroczek N, Schuster D, Snyder A, Rabinowitz A, Arnett P, Schatz P, Cameron N, Stolberg P, Hart J, Jones W, Mayfield J, Allen D, Sullivan K, Edmed S, Vanderploeg R, Silva M, Vaughan C, McGuire E, Gerst E, Fricke S, VanMeter J, Newman J, Gioia G, Vaughan C, VanMeter J, McGuire E, Gioia G, Newman J, Gerst E, Fricke S, Wahlberg A, Zelonis S, Chatterjee A, Smith S, Whipple E, Mace L, Manning K, Ang J, Schultheis M, Wilk J, Herrell R, Hoge C, Zakzanis K, Yu S, Jeffay E, Zimmer A, Webbe F, Piecora K, Schuster D, Zimmer A, Piecora K, Schuster D, Webbe F, Adler M, Holster J, Golden C, Andrews A, Schleicher-Dilks S, Golden C, Arffa S, Thornton J, Arffa S, Thornton J, Arffa S, Thornton J, Arffa S, Thornton J, Canas A, Sevadjian C, Fournier A, Miller D, Maricle D, Donders J, Larsen T, Gidley Larson J, Sheehan J, Suchy Y, Higgins K, Rolin S, Dunham K, Akeson S, Horton A, Reynolds C, Horton A, Reynolds C, Jordan L, Gonzalez S, Heaton S, McAlister C, Tam J, Schmitter-Edgecombe M, Olivier T, West S, Golden C, Prinzi L, Martin P, Robbins J, Bruzinski B, Golden C, Riccio C, Blakely A, Yoon M, Reynolds C, Robbins J, Prinzi L, Martin P, Golden C, Schleicher-Dilks S, Andrews A, Adler M, Pearlson J, Golden C, Sevadjian C, Canas A, Fournier A, Miller D, Maricle D, Sheehan J, Gidley LJ, Suchy Y, Sherman E, Carlson H, Gaxiola-Valdez I, Wei X, Beaulieu C, Hader W, Brooks B, Kirton A, Barlow K, Hrabok M, Mohamed I, Wiebe S, Smith K, Ailion A, Ivanisevic M, King T, Smith K, King T, Thorgusen S, Bowman D, Suchy Y, Walsh K, Mitchell F, Jill G, Iris P, Ross K, Madan-Swain A, Gioia G, Isquith P, Webber D, DeFilippis N, Collins M, Hill F, Weber R, Johnson A, Wiley C, Zimmerman E, Burns T, DeFilippis N, Ritchie D, Odland A, Stevens A, Mittenberg W, Hartlage L, Williams B, Weidemann E, Demakis G, Avila J, Razani J, Burkhart S, Adams W, Edwards M, O'Bryant S, Hall J, Johnson L, Grammas P, Gong G, Hargrave K, Mattevada S, Barber R, Hall J, Vo H, Johnson L, Barber R, O'Bryant S, Hill B, Davis J, O'Connor K, Musso M, Rehm-Hamilton T, Ploetz D, Rohling M, Rodriguez M, Potter E, Loewenstein D, Duara R, Golden C, Velamuri S, Rinehardt E, Schoenberg M, Mattingly M, Kaufman R, Rosado Y, Boseck J, Tiberi N, McCormick C, Davis A, Hernandez Finch M, Gelder B, Cannon M, McGregor S, Reitman D, Rey J, Scarisbrick D, Holdnack J, Iverson G, Thaler N, Bello D, Whoolery H, Etcoff L, Vekaria P, Whittington L, Nemeth D, Gremillion A, Olivier T, Amirthavasagam S, Jeffay E, Zakzanis K, Barney S, Umuhoza D, Strauss G, Knatz-Bello D, Allen D, Bolanos J, Bell J, Restrepo L, Frisch D, Golden C, Hartlage L, Williams B, Iverson G, McIntosh D, Kjernisted K, Young A, Kiely T, Tai C, Gomez R, Schatzberg A, Keller J, Rhodes E, Ajilore O, Zhang A, Kumar A, Lamar M, Ringdahl E, Sutton G, Turner A, Snyder J, Allen D, Verbiest R, Thaler N, Strauss G, Allen D, Walkenhorst E, Crowe S, August-Fedio A, Sexton J, Cummings S, Brown K, Fedio P, Grigorovich A, Fish J, Gomez M, Leach L, Lloyd H, Nichols M, Goldberg M, Novakovic-Agopian T, Chen A, Abrams G, Rossi A, Binder D, Muir J, Carlin G, Murphy M, McKim R, Fitsimmons R, D'Esposito M, Shevchik K, McCaw W, Schrock B, Vernon A, Frank R, Ona PZ, Freitag E, Weber E, Woods S, Kellogg E, Grant I, Basso M, Dyer B, Daniel M, Michael P, Fontanetta R, Martin P, Golden C, Gass C, Stripling A, Odland A, Holster J, Corsun-Ascher C, Olivier T, Golden C, Legaretta M, Vik P, Van Ness E, Fowler B, Noll K, Denney D, Wiechman A, Stephanie T, Greenberg B, Lacritz L, Padua M, Sandhu K, Moses J, Sordahl J, Anderson J, Wheaton V, Anderson J, Berggren K, Cheung D, Luber H, Loftis J, Huckans M, Bennett T, Dawson C, Soper H, Bennett T, Soper H, Carter K, Hester A, Ringe W, Spence J, Posamentier M, Hart J, Haley R, Fallows R, Pella R, McCoy K, O'Rourke J, Hilsabeck R, Fallows R, Pella R, McCoy K, O'Rourke J, Hilsabeck R, Gass C, Curiel R, Gass C, Stripling A, Odland A, Goldberg M, Lloyd H, Gremillion A, Nemeth D, Whittington L, Hu E, Vik P, Dasher N, Fowler B, Jeffay E, Zakzanis K, Jordan S, DeFilippis N, Collins M, Goetsch V, Small S, Mansoor Y, Homer-Smith E, Lockwood C, Moses J, Martin P, Odland A, Fontanetta R, Sharma V, Golden C, Odland A, Martin P, Perle J, Gass C, Simco E, Mittenberg W, Patt V, Minassian A, Perry W, Polott S, Webbe F, Mulligan K, Shaneyfelt K, Wall J, Thompson J, Tai C, Kiely T, Compono V, Trettin L, Gomez R, Schatzberg A, Keller J, Tsou J, Pearlson J, Sharma V, Tourgeman I, Golden C, Waldron-Perrine B, Tree H, Spencer R, McGuire A, Na S, Pangilinan P, Bieliauskas L, You S, Moses J, An K, Jeffay E, Zakzanis K, Biddle C, Fazio R, Willett K, Rolin S, O'Grady M, Denney R, Bresnan K, Erlanger D, Seegmiller R, Kaushik T, Brooks B, Krol A, Carlson H, Sherman E, Davis J, McHugh T, Axelrod B, Hanks R. Grand Rounds. Arch Clin Neuropsychol 2011. [DOI: 10.1093/arclin/acr056] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Lawniczak MKN, Emrich SJ, Holloway AK, Regier AP, Olson M, White B, Redmond S, Fulton L, Appelbaum E, Godfrey J, Farmer C, Chinwalla A, Yang SP, Minx P, Nelson J, Kyung K, Walenz BP, Garcia-Hernandez E, Aguiar M, Viswanathan LD, Rogers YH, Strausberg RL, Saski CA, Lawson D, Collins FH, Kafatos FC, Christophides GK, Clifton SW, Kirkness EF, Besansky NJ. Widespread divergence between incipient Anopheles gambiae species revealed by whole genome sequences. Science 2010; 330:512-4. [PMID: 20966253 DOI: 10.1126/science.1195755] [Citation(s) in RCA: 223] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
The Afrotropical mosquito Anopheles gambiae sensu stricto, a major vector of malaria, is currently undergoing speciation into the M and S molecular forms. These forms have diverged in larval ecology and reproductive behavior through unknown genetic mechanisms, despite considerable levels of hybridization. Previous genome-wide scans using gene-based microarrays uncovered divergence between M and S that was largely confined to gene-poor pericentromeric regions, prompting a speciation-with-ongoing-gene-flow model that implicated only about 3% of the genome near centromeres in the speciation process. Here, based on the complete M and S genome sequences, we report widespread and heterogeneous genomic divergence inconsistent with appreciable levels of interform gene flow, suggesting a more advanced speciation process and greater challenges to identify genes critical to initiating that process.
Collapse
Affiliation(s)
- M K N Lawniczak
- Division of Cell and Molecular Biology, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Palakurthi S, Grondine S, Gingles N, Rong X, Lawson D, Hall P, Cao Y, Wu K, Reimer C. 139 Inhibition of osteolysis by CSF-1R antagonist in MM.1S orthotopic multiple myeloma model. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71844-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Kersey PJ, Lawson D, Birney E, Derwent PS, Haimel M, Herrero J, Keenan S, Kerhornou A, Koscielny G, Kähäri A, Kinsella RJ, Kulesha E, Maheswari U, Megy K, Nuhn M, Proctor G, Staines D, Valentin F, Vilella AJ, Yates A. Ensembl Genomes: extending Ensembl across the taxonomic space. Nucleic Acids Res 2009; 38:D563-9. [PMID: 19884133 PMCID: PMC2808935 DOI: 10.1093/nar/gkp871] [Citation(s) in RCA: 116] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Ensembl Genomes (http://www.ensemblgenomes.org) is a new portal offering integrated access to genome-scale data from non-vertebrate species of scientific interest, developed using the Ensembl genome annotation and visualisation platform. Ensembl Genomes consists of five sub-portals (for bacteria, protists, fungi, plants and invertebrate metazoa) designed to complement the availability of vertebrate genomes in Ensembl. Many of the databases supporting the portal have been built in close collaboration with the scientific community, which we consider as essential for maintaining the accuracy and usefulness of the resource. A common set of user interfaces (which include a graphical genome browser, FTP, BLAST search, a query optimised data warehouse, programmatic access, and a Perl API) is provided for all domains. Data types incorporated include annotation of (protein and non-protein coding) genes, cross references to external resources, and high throughput experimental data (e.g. data from large scale studies of gene expression and polymorphism visualised in their genomic context). Additionally, extensive comparative analysis has been performed, both within defined clades and across the wider taxonomy, and sequence alignments and gene trees resulting from this can be accessed through the site.
Collapse
Affiliation(s)
- P J Kersey
- EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SD, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Petrofsky J, Schwab E, Cúneo M, George J, Kim J, Almalty A, Lawson D, Johnson E, Remigo W. Current distribution under electrodes in relation to stimulation current and skin blood flow: are modern electrodes really providing the current distribution during stimulation we believe they are? J Med Eng Technol 2009; 30:368-81. [PMID: 17060165 DOI: 10.1080/03091900500183855] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Carbonized rubber electrodes were tested extensively when they were first developed 30 years ago, but modern carbonized rubber electrodes have not received the type of scrutiny that the first electrodes received. Modern electrodes differ from the original electrodes in that they come with a self-adhesive electrode gel called hydrogel as part of their composition. The present study was undertaken to examine the current distribution and impedance characteristics of five brands of carbonized rubber electrodes and to examine the current distribution between electrodes during electrical stimulation in six subjects. Several different electrode sizes were tested between 3 and 10 cm. The current flow between the electrodes was determined by measuring the voltage across the skin on human subjects in 15 discrete locations between the electrodes. Blood flow was also measured between the electrodes with a laser Doppler flow meter to assess the physiological effect of current distribution on the skin at several skin temperatures. The results of these studies showed that at low currents, such as is used in TENS, very little current is actually applied through the skin due to the high impedance of the electrodes. At current levels normally used for electrical stimulation for functional movement, while current flow is better in most electrodes, it is very uneven, resulting in high current density in the centre of the electrodes and a fall off of at least 50% in current intensity at the edges of the electrode. There was very little difference in current density between small and large electrodes due to the high current density in the centre. Skin blood flow altered the movement of current between the electrodes and also may contribute to electrode performance. The implication of these studies is that electrode design needs to be altered for better current distribution, especially at low stimulation currents.
Collapse
Affiliation(s)
- J Petrofsky
- Department of Physical Therapy, Loma Linda University, Loma Linda, California 92350, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, Gailani F, Riley LB, Vena D, Hwu P. A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.18_suppl.cra9011] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA9011 Background: In a phase II study, 13 (42%) of 31 patients with metastatic melanoma receiving high-dose (HD) IL-2 plus gp100:209–217(210M) peptide experienced objective responses (S.A. Rosenberg, et al, Nature Medicine 4: 321–327, 1998). Other studies showed a lower response rate (RR) but no randomized studies have been done. Methods: A prospective randomized phase III trial was conducted at 21 centers with 185 patients. Eligibility: stage IV or locally advanced stage III cutaneous melanoma, HLA A0201, no brain metastases, eligible for HD IL-2, and no previous HD IL-2 or gp100:209–217(210M). Arm 1 received HD IL-2 alone (720,000 IU/kg/dose) and Arm 2 gp100:209–217(210M) peptide + Montanide ISA followed by HD IL-2. The primary objective was clinical response. Secondary objectives were toxicity, disease free/progression free survival, immunologic response and quality of life. Central HLA typing, pathology review, and blinded response assessment were done at the NIH. Central data monitoring was done by The EMMES Corp. and a Data Safety Monitoring Board. Results: Numbers of patients enrolled, treated, and evaluable for response in Arm 1 were 94, 93, and 93 respectively; in Arm 2 91, 86, and 86. Toxicities were consistent with HD IL-2 ± vaccine. Investigator assessed RR showed significant improvement in overall RR for Arm 2=22.1% vs 9.7% (P=0.0223, Chi-Square) and progression free survival (PFS) in favor of Arm 2=2.9 months (1.7–4.5) vs 1.6 (1.5–1.8) (P=0.0101). Median overall survival favors Arm 2=17.6 months (11.8–26.6) vs 12.8 (8.7–16.3) (P=0.0964). Blinded response review is ongoing. Conclusions: RR and PFS were superior with peptide vaccine and HD IL-2 compared to HD IL-2 alone. This represents the first evidence of clinical benefit of vaccination in patients with melanoma. [Table: see text]
Collapse
Affiliation(s)
- D. J. Schwartzentruber
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - D. Lawson
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - J. Richards
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - R. M. Conry
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - D. Miller
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - J. Triesman
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - F. Gailani
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - L. B. Riley
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - D. Vena
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - P. Hwu
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
23
|
Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, Gailani F, Riley LB, Vena D, Hwu P. A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.cra9011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA9011 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Collapse
Affiliation(s)
- D. J. Schwartzentruber
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - D. Lawson
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - J. Richards
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - R. M. Conry
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - D. Miller
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - J. Triesman
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - F. Gailani
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - L. B. Riley
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - D. Vena
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| | - P. Hwu
- Center for Cancer Care, Goshen, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Lutheran General Hospital Cancer Care Center, Park Ridge, IL; UAHSF Comprehensive Cancer Center, Birmingham, AL; James Graham Brown Cancer Center, Louisville, KY; Medical Consultants, Milwaukee, WI; Riverside Creek Medical Center, Riverside, CA; St. Luke's Hospital, Bethlehem, PA; The EMMES Corporation, Rockville, MD; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
24
|
Loquai C, Pavlick A, Lawson D, Gutzmer R, Richards J, Gore ME, de Boer CJ, Uhlar C, Lang Z, O'Day S. Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9029] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9029 Objectives: Evaluate the safety and efficacy of CNTO 95, a human anti-αv integrin monoclonal antibody, when administered alone or in combination with dacarbazine (DTIC). Methods: Patients with Stage IV metastatic melanoma were randomized 1:1:1:1 to receive 5 or 10mg/kg CNTO 95 alone, or DTIC (1000mg/m2) + either 10mg/kg CNTO 95 or placebo administered intravenously once every 3 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. DTIC arms were blinded; single-agent arms were open-label. The primary endpoint was progression free survival (PFS); secondary endpoints included partial response (PR), complete response (CR), stable disease (SD) and overall survival (OS). Major safety endpoints included the incidence of adverse events (AEs) and serious AEs (SAEs). Results: Patients were randomized to receive 5mg/kg CNTO 95 (n=32), 10mg/kg CNTO 95 (n=33), CNTO 95+DTIC (n=32), or placebo+DTIC (n=32). Baseline demographics were similar across groups. The median PFS for CNTO 95+DTIC was 75 days, placebo+DTIC was 54 days and both CNTO 95 alone arms were 42 days. Six patients achieved PR (2–10mg/kg CNTO 95, 1-CNTO 95+DTIC, 3-placebo+DTIC); one patient achieved CR (CNTO 95+DTIC). A higher proportion (43.3%) of patients achieved SD ≥ 12 wks in the CNTO 95+DTIC group compared with the other 3 groups (<20.0%). The median survival was 11.0 months for the patients in the CNTO 95+DTIC arm, 9.8 months and 14.9 months for the 5mg/kg and 10mg/kg arms, and 8.0 months for those in the DTIC control arm. The most common AEs were headache, nausea, fatigue, pyrexia, vomiting and transient uveitic reactions. Three patients (1–5mg/kg, 2-CNTO 95+DTIC) discontinued treatment due to AEs. A higher proportion of patients experienced SAEs in the placebo+DTIC group (29.0%) than in the 5mg/kg (12.9%), 10mg/kg (16.2%) or CNTO 95+DTIC (18.8%) groups. Conclusions: CNTO 95 alone or combined with DTIC was generally well tolerated. In patients with Stage IV metastatic melanoma, a trend toward improvement in PFS, OS and disease control was demonstrated with CNTO 95+DTIC. Centocor, Centocor Research and Development, Inc. Centocor Research and Development, Inc. Johnson & Johnson Centocor Research and Development, Inc. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Loquai
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - A. Pavlick
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - D. Lawson
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - R. Gutzmer
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - J. Richards
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - M. E. Gore
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - C. J. de Boer
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - C. Uhlar
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - Z. Lang
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| | - S. O'Day
- Universitaetsklinikum Essen, Essen, Germany; New York University, New York, NY; Emory University, Atlanta, GA; Medizinische Hochschule Hannover, Hannover, Germany; Oncology Specialists, S.C., Park Ridge, IL; Royal Marsden Hospital, London, United Kingdom; Centocor B.V., Leiden, Netherlands; Centocor Research and Development, Inc., Malvern, PA; Angeles Clinic and Research Institute, Santa Monica, CA
| |
Collapse
|
25
|
Petrofsky J, Lawson D, Prowse M, Suh HJ. Effects of a 2-, 3- and 4-electrode stimulator design on current dispersion on the surface and into the limb during electrical stimulation in controls and patients with wounds. J Med Eng Technol 2009; 32:485-97. [PMID: 19005963 DOI: 10.1080/03091900701574407] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Electrical stimulation is a widely used modality in the field of physical therapy and exercise physiology. The most common method for the application of electrical stimulation is a two-electrode system where one electrode is the source and the other is a reference. However, recent studies report that a more effective delivery system can be achieved if more than two electrodes are used. In the present investigation, the circuitry to deliver electrical stimulation through a 2-, 3- or 4-electrode delivery system was designed. The system was evaluated by its ability to deliver current on the surface of the skin as well as deep into the quadriceps muscle in six control subjects and in and around wounds in six other subjects. The results of the experiments showed that much better depth of penetration was achieved in a 4-electrode system (one electrode was on the opposite side of the limb and three electrodes were on top of the limb) than in either a 2- or a 3-electrode delivery system. In non-wounded skin, given the same current from the stimulator, the current in the quadriceps muscle was found to be double with a 4-electrode versus a 2-electrode system. In wounds, this same finding was seen. Here, blood flow, an indicator of the effectiveness of electrical stimulation in wounds, was three times higher if a multi-channel stimulator was used versus a 2-channel stimulator. Thus a multi-channel electrical stimulation system is more effective than a 2-electrode system.
Collapse
Affiliation(s)
- J Petrofsky
- Department of Physical Therapy, Loma Linda University, Loma Linda, CA 92350, USA.
| | | | | | | |
Collapse
|
26
|
Hanley KZ, Siddiqui MT, Lawson D, Cohen C, Nassar A. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Diagn Cytopathol 2009; 37:251-7. [DOI: 10.1002/dc.20989] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
27
|
Dhanasekaran R, Khanna V, Lawson D, Delman K, Kim H. Abstract No. 167: Survival Benefits of Yttrium-90 Radioembolization (SIR-Spheres) for Hepatic Metastasis from Melanoma: Preliminary Study. J Vasc Interv Radiol 2009. [DOI: 10.1016/j.jvir.2008.12.154] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
28
|
Hubbard TJP, Aken BL, Ayling S, Ballester B, Beal K, Bragin E, Brent S, Chen Y, Clapham P, Clarke L, Coates G, Fairley S, Fitzgerald S, Fernandez-Banet J, Gordon L, Graf S, Haider S, Hammond M, Holland R, Howe K, Jenkinson A, Johnson N, Kahari A, Keefe D, Keenan S, Kinsella R, Kokocinski F, Kulesha E, Lawson D, Longden I, Megy K, Meidl P, Overduin B, Parker A, Pritchard B, Rios D, Schuster M, Slater G, Smedley D, Spooner W, Spudich G, Trevanion S, Vilella A, Vogel J, White S, Wilder S, Zadissa A, Birney E, Cunningham F, Curwen V, Durbin R, Fernandez-Suarez XM, Herrero J, Kasprzyk A, Proctor G, Smith J, Searle S, Flicek P. Ensembl 2009. Nucleic Acids Res 2008; 37:D690-7. [PMID: 19033362 PMCID: PMC2686571 DOI: 10.1093/nar/gkn828] [Citation(s) in RCA: 683] [Impact Index Per Article: 42.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The Ensembl project (http://www.ensembl.org) is a comprehensive genome information system featuring an integrated set of genome annotation, databases, and other information for chordate, selected model organism and disease vector genomes. As of release 51 (November 2008), Ensembl fully supports 45 species, and three additional species have preliminary support. New species in the past year include orangutan and six additional low coverage mammalian genomes. Major additions and improvements to Ensembl since our previous report include a major redesign of our website; generation of multiple genome alignments and ancestral sequences using the new Enredo-Pecan-Ortheus pipeline and development of our software infrastructure, particularly to support the Ensembl Genomes project (http://www.ensemblgenomes.org/).
Collapse
Affiliation(s)
- T J P Hubbard
- Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Laing N, McDermott B, Wen S, Pandya M, Mazzola A, Lawson D, Hall P, Drake A, Klakamp S, Cao Z. 535 POSTER Characterization of a fully human PDGFRa antibody that reduces tumor growth and stromal infiltration in a xenograft model of non-small cell lung cancer. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72469-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
30
|
Megy K, Hammond M, Lawson D, Bruggner RV, Birney E, Collins FH. Genomic resources for invertebrate vectors of human pathogens, and the role of VectorBase. Infect Genet Evol 2008; 9:308-13. [PMID: 18262474 DOI: 10.1016/j.meegid.2007.12.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2007] [Revised: 12/19/2007] [Accepted: 12/20/2007] [Indexed: 11/26/2022]
Abstract
High-throughput genome sequencing techniques have now reached vector biology with an emphasis on those species that are vectors of human pathogens. The first mosquito to be sequenced was Anopheles gambiae, the vector for Plasmodium parasites that cause malaria. Further mosquitoes have followed: Aedes aegypti (yellow fever and dengue fever vector) and Culex pipiens (lymphatic filariasis and West Nile fever). Species that are currently in sequencing include the body louse Pediculus humanus (Typhus vector), the triatomine Rhodnius prolixus (Chagas disease vector) and the tick Ixodes scapularis (Lyme disease vector). The motivations for sequencing vector genomes are to further understand vector biology, with an eye on developing new control strategies (for example novel chemical attractants or repellents) or understanding the limitations of current strategies (for example the mechanism of insecticide resistance); to analyse the mechanisms driving their evolution; and to perform an exhaustive analysis of the gene repertory. The proliferation of genomic data creates the need for efficient and accessible storage. We present VectorBase, a genomic resource centre that is both involved in the annotation of vector genomes and act as a portal for access to the genomic information (http://www.vectorbase.org).
Collapse
Affiliation(s)
- K Megy
- EMBL, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK.
| | | | | | | | | | | |
Collapse
|
31
|
Flicek P, Aken BL, Beal K, Ballester B, Caccamo M, Chen Y, Clarke L, Coates G, Cunningham F, Cutts T, Down T, Dyer SC, Eyre T, Fitzgerald S, Fernandez-Banet J, Gräf S, Haider S, Hammond M, Holland R, Howe KL, Howe K, Johnson N, Jenkinson A, Kähäri A, Keefe D, Kokocinski F, Kulesha E, Lawson D, Longden I, Megy K, Meidl P, Overduin B, Parker A, Pritchard B, Prlic A, Rice S, Rios D, Schuster M, Sealy I, Slater G, Smedley D, Spudich G, Trevanion S, Vilella AJ, Vogel J, White S, Wood M, Birney E, Cox T, Curwen V, Durbin R, Fernandez-Suarez XM, Herrero J, Hubbard TJP, Kasprzyk A, Proctor G, Smith J, Ureta-Vidal A, Searle S. Ensembl 2008. Nucleic Acids Res 2007; 36:D707-14. [PMID: 18000006 PMCID: PMC2238821 DOI: 10.1093/nar/gkm988] [Citation(s) in RCA: 370] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The Ensembl project (http://www.ensembl.org) is a comprehensive genome information system featuring an integrated set of genome annotation, databases and other information for chordate and selected model organism and disease vector genomes. As of release 47 (October 2007), Ensembl fully supports 35 species, with preliminary support for six additional species. New species in the past year include platypus and horse. Major additions and improvements to Ensembl since our previous report include extensive support for functional genomics data in the form of a specialized functional genomics database, genome-wide maps of protein–DNA interactions and the Ensembl regulatory build; support for customization of the Ensembl web interface through the addition of user accounts and user groups; and increased support for genome resequencing. We have also introduced new comparative genomics-based data mining options and report on the continued development of our software infrastructure.
Collapse
Affiliation(s)
- P Flicek
- European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Gonzalez R, Lewis K, Samlowski W, Cranmer L, Catlett J, Kirkwood J, Whitman E, Lawson D, Bartels P, Drake T. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8538] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8538 Background: In cell line studies, YM155 showed markedly potent antiproliferative activity against melanoma with 50% growth inhibition (GI50) values ranging from 0.35 nM to 910 nM. In melanoma tumor-bearing mouse xenograft models, YM155 showed significant antitumor activity including regression of tumors, at doses ranging from 1 to 10 mg/kg/day. Methods: Chemotherapy naive patients with unresectable Stage III or IV melanoma were eligible. The primary endpoint was tumor response defined by RECIST criteria. Secondary endpoints included progression-free survival and toxicity. A Simon's two stage minimax design was utilized with the first stage requiring 1 response (N=27) and a total of 2 responses required at the conclusion of stage II (N=29). Patients were considered evaluable if they completed 2 cycles. YM155 was given as a 168-hour (7-day) continuous infusion every three weeks (1 cycle) at a dose of 4.8 mg/m2/day. Results: Enrollment is complete at 34 pts in order to reach 29 evaluable with treatment ongoing. Results are available for the first 26 pts. Median age was 59 y/o, (range 29 - 88) with ECOG PS of 0–1. There is one objective response of intrabdominal lymph nodes based on Investigator assessment at Cycle 2 confirmed at Cycle 4; another patient had a minor response (24% reduction) at Cycle 6 (currently at Cycle 8). Two subjects have shown stable disease after 6 cycles and remain on study. The median number of cycles is 3 (range 1 - 9). Two of 26 pts reported a grade 3 AE considered possibly related to YM155 (chest pain - nos and catheter related thrombosis). Nineteen of 26 pts have discontinued the study (18 PD, 1 withdrew consent). Conclusions: YM155 induced responses in 2 pts and was generally well tolerated. Given this encouraging response as a single agent, studies of YM155 combined with other agents are under consideration. [Table: see text]
Collapse
Affiliation(s)
- R. Gonzalez
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - K. Lewis
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - W. Samlowski
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - L. Cranmer
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - J. Catlett
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - J. Kirkwood
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - E. Whitman
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - D. Lawson
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - P. Bartels
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - T. Drake
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| |
Collapse
|
33
|
O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, McLeod M, Hurwitz C, Haddad J, Jacobson E. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8528] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8528 Background: STA-4783 (S), an inducer of heat shock protein 70 (hsp70) is a bis-thiobenzoylhydrazide compound. S leads to up-regulation of hsp70 in tumor cell lines. Xenograft models of solid tumors showed synergistic anti-tumor activity in combination with paclitaxel (P). The combination P + S, in phase I and II studies, showed dose-related hsp70 induction (evidence of biological activity) and tolerability. Methods: Eligibility was based on a diagnosis of metastatic cutaneous melanoma, ECOG <=2, and prior treatment with 1 or no chemotherapy regimens. A total of 81 patients (pts) were randomized 2:1 (P 80 mg/m2 + S 213 mg/m2:P 80 mg/m2) 3 weeks out of 4 at 21 US clinical sites. The primary endpoint was progression free survival (PFS); secondary endpoints were response rate (RR), and adverse events (AEs). Results: Based on intent-to-treat analysis, the median PFS was 3.68 months (m) for P + S vs. 1.84 m in the P only arm (p=.035). RR was 15.1% in the P + S arm and 3.6% in the P arm. Subgroup analysis showed chemo- naive pts (n=23) with P + S showed a median PFS of 8.28 m vs. 2.40 in the P arm (n=9). For pts with 1 prior chemotherapy, (n=29), PFS on P + S was 3.12 m vs. 1.77 m on P (n=19). Of 19 pts who crossed over at progression, data are available for 14. PFS ranged from 0.72 to 5.5 m. Three of the 14 evaluable pts treated with P alone had rapid progression (0.95, 1.6, and 1.7 m) then significant inversion of the time to progression with the addition of S to P (2.3, 5.5, and 4.2 m) suggesting study drug effect. Scans were done at identical intervals (8 weeks). The proportion of pts with AEs of grade 3 or higher was 54% (n=52) in the P + S group and 57% in the P group (n=28); pts on P received a median of 2 cycles, while pts in the P + S group received a median of 4. Adverse events leading to discontinuation were low in both groups: 10% for the P + S, and 14% for P. Conclusions: The addition of S to P showed an increase in PFS vs. P alone particularly in chemo-naïve pts. A few pts failing single agent P appeared to benefit from P + S. Despite the additional treatment duration in the P + S group the drugs were well- tolerated, and showed mainly P related adverse events. A phase III study is planned to confirm a role for P + S in metastatic melanoma. [Table: see text]
Collapse
Affiliation(s)
- S. O'Day
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - R. Gonzalez
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - D. Lawson
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - R. Weber
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - L. Hutchins
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - C. Anderson
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - M. McLeod
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - C. Hurwitz
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - J. Haddad
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| | - E. Jacobson
- The Angeles Clinic and Research Institute, Santa Monica, CA; University of Colorado Health Sciences Center, Aurora, CO; Emory Winship Cancer Institute, Atlanta, GA; St. Francis Memorial Hospital, San Francisco, CA; University of Arkansas for Medical Sciences, Little Rock, AR; Ellis Fischel Cancer Center, Columbia, MO; Synta Pharmaceuticals, Lexington, MA
| |
Collapse
|
34
|
Hubbard TJP, Aken BL, Beal K, Ballester B, Caccamo M, Chen Y, Clarke L, Coates G, Cunningham F, Cutts T, Down T, Dyer SC, Fitzgerald S, Fernandez-Banet J, Graf S, Haider S, Hammond M, Herrero J, Holland R, Howe K, Howe K, Johnson N, Kahari A, Keefe D, Kokocinski F, Kulesha E, Lawson D, Longden I, Melsopp C, Megy K, Meidl P, Ouverdin B, Parker A, Prlic A, Rice S, Rios D, Schuster M, Sealy I, Severin J, Slater G, Smedley D, Spudich G, Trevanion S, Vilella A, Vogel J, White S, Wood M, Cox T, Curwen V, Durbin R, Fernandez-Suarez XM, Flicek P, Kasprzyk A, Proctor G, Searle S, Smith J, Ureta-Vidal A, Birney E. Ensembl 2007. Nucleic Acids Res 2006; 35:D610-7. [PMID: 17148474 PMCID: PMC1761443 DOI: 10.1093/nar/gkl996] [Citation(s) in RCA: 657] [Impact Index Per Article: 36.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The Ensembl (http://www.ensembl.org/) project provides a comprehensive and integrated source of annotation of chordate genome sequences. Over the past year the number of genomes available from Ensembl has increased from 15 to 33, with the addition of sites for the mammalian genomes of elephant, rabbit, armadillo, tenrec, platypus, pig, cat, bush baby, common shrew, microbat and european hedgehog; the fish genomes of stickleback and medaka and the second example of the genomes of the sea squirt (Ciona savignyi) and the mosquito (Aedes aegypti). Some of the major features added during the year include the first complete gene sets for genomes with low-sequence coverage, the introduction of new strain variation data and the introduction of new orthology/paralog annotations based on gene trees.
Collapse
Affiliation(s)
- T J P Hubbard
- Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Harris WB, Assikis V, Yin-Goen Q, Lewis MM, Lawson D, Amin MB, Young AN, Petros JA. Neuroendocrine cancer of the kidney: Clinical implications of expression microarray analysis. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20093 Background: Conventional clinical trial strategies cannot be used to develop new therapies for rare malignancies. Neuroendocrine neoplasms of the kidney are extremely rare. Here we compare the gene expression profiles of a neuroendocrine tumor from a 32 year old male with a horseshoe kidney, a large renal primary and metastatic thyroid lesions to the profiles of other cancers. Response to systemic therapy is also reported. The ultimate objective of this project is to identify new therapeutic targets for patient-specific cancer therapy. Methods: After informed consent, tissue from the patient was analyzed by cytology and immunohistochemistry. Total RNA was isolated from formalin-fixed paraffin-embedded archival reference tissues with Arcturus Paradise Reagents. Gene expression was analyzed with Affymetrix X3P arrays of the entire expressed genome. A supervised significance analysis of microarrays (SAM) procedure, using 400 data permutations, was performed to identify gene products that were differentially expressed. Clinical outcomes were documented in the patient’s medical record on the basis of standard medical imaging. Results: Cytology, immunohistochemistry and microarray studies revealed similar patterns for the primary and metastatic lesions. Gene expression profiles of the patient’s kidney and thyroid lesions, as well as other kidney and neuroendocrine tumors, identified 11 genes overexpressed significantly in the neuroendocrine tumors. Each was associated with neuroendocrine biology. The patient had a mixed response to chemotherapy with gemcitabine and cisplatin and progressive disease after 3 monthly treatments with sandostatin. He awaits assessment of response to metaiodobenzylguanidine (MIBG). Conclusions: Gene expression profiling was effective in characterizing an unusual case of renal cancer with metastasis to thyroid, though no new therapeutic target has yet been identified. Comparing response or resistance to therapy with microarray analysis may prove to be an effective strategy for developing patient-specific cancer therapy. This work was supported, in part, by a VA Merit Review Award. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. B. Harris
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - V. Assikis
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - Q. Yin-Goen
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - M. M. Lewis
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - D. Lawson
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - M. B. Amin
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - A. N. Young
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| | - J. A. Petros
- Emory University School of Medicine, Atlanta, GA; Atlanta VA Medical Center, Atlanta, GA
| |
Collapse
|
36
|
Atkins MB, Sosman J, Agarwala S, Logan T, Clark J, Ernstoff M, Lawson D, Dutcher J, Weiss G, Urba W, Margolin K. A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7552] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. B. Atkins
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - J. Sosman
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - S. Agarwala
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - T. Logan
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - J. Clark
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - M. Ernstoff
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - D. Lawson
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - J. Dutcher
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - G. Weiss
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - W. Urba
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - K. Margolin
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| |
Collapse
|
37
|
Liu YQ, Keane M, Ensell M, Miller W, Kashon M, Ong TM, Mauderly J, Lawson D, Gautam M, Zielinska B, Whitney K, Eberhardt J, Wallace W. In vitro genotoxicity of exhaust emissions of diesel and gasoline engine vehicles operated on a unified driving cycle. ACTA ACUST UNITED AC 2004; 7:60-6. [PMID: 15614403 DOI: 10.1039/b407375d] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Acetone extracts of engine exhaust particulate matter (PM) and of vapor-phase semi-volatile organic compounds (SVOCs) collected from a set of 1998-2000 model year normal emitter diesel engine automobile or light trucks and from a set of 1982-1996 normal emitter gasoline engine automobiles or light trucks operated on the California Unified Driving Cycle at 22 [degree]C were assayed for in vitro genotoxic activities. Gasoline and diesel PM were comparably positive mutagens for Salmonella typhimurium strains YG1024 and YG1029 on a mass of PM extract basis with diesel higher on a mileage basis; gasoline SVOC was more active than diesel on an extracted-mass basis, with diesel SVOC more active on a mileage basis. For chromosomal damage indicated by micronucleus induction in Chinese hamster lung fibroblasts (V79 cells), diesel PM expressed about one-tenth that of gasoline PM on a mass of extract basis, but was comparably active on a mileage basis; diesel SVOC was inactive. For DNA damage in V79 cells indicated by the single cell gel electrophoresis (SCGE) assay, gasoline PM was positive while diesel PM was active at the higher doses; gasoline SVOC was active with toxicity preventing measurement at high doses, while diesel SVOC was inactive at all but the highest dose.
Collapse
Affiliation(s)
- Yu-Qing Liu
- National Institute for Occupational Safety and Health, 1095 Willowdale Rd., Morgantown, WV 26505, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Peereboom D, Carson K, Lawson D, Lesser G, Supko J, Grossman S. A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Peereboom
- Cleveland Clinic Brain Tumor Institute, Cleveland, OH; Johns Hopkins Oncology Center, Baltimore, MD; Emory University, Atlanta, GA; Wake Forest University, Winston-Salem, NC; MGH Cancer Center, Boston, MA
| | - K. Carson
- Cleveland Clinic Brain Tumor Institute, Cleveland, OH; Johns Hopkins Oncology Center, Baltimore, MD; Emory University, Atlanta, GA; Wake Forest University, Winston-Salem, NC; MGH Cancer Center, Boston, MA
| | - D. Lawson
- Cleveland Clinic Brain Tumor Institute, Cleveland, OH; Johns Hopkins Oncology Center, Baltimore, MD; Emory University, Atlanta, GA; Wake Forest University, Winston-Salem, NC; MGH Cancer Center, Boston, MA
| | - G. Lesser
- Cleveland Clinic Brain Tumor Institute, Cleveland, OH; Johns Hopkins Oncology Center, Baltimore, MD; Emory University, Atlanta, GA; Wake Forest University, Winston-Salem, NC; MGH Cancer Center, Boston, MA
| | - J. Supko
- Cleveland Clinic Brain Tumor Institute, Cleveland, OH; Johns Hopkins Oncology Center, Baltimore, MD; Emory University, Atlanta, GA; Wake Forest University, Winston-Salem, NC; MGH Cancer Center, Boston, MA
| | - S. Grossman
- Cleveland Clinic Brain Tumor Institute, Cleveland, OH; Johns Hopkins Oncology Center, Baltimore, MD; Emory University, Atlanta, GA; Wake Forest University, Winston-Salem, NC; MGH Cancer Center, Boston, MA
| |
Collapse
|
39
|
Turic D, Langley K, Mills S, Stephens M, Lawson D, Govan C, Williams N, Van Den Bree M, Craddock N, Kent L, Owen M, O'Donovan M, Thapar A. Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. Mol Psychiatry 2004; 9:169-73. [PMID: 14966475 DOI: 10.1038/sj.mp.4001387] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Attention deficit hyperactivity disorder (ADHD) is a childhood onset disorder, for which there is good evidence that genetic factors contribute to the aetiology. Recently reported linkage findings suggested evidence of a susceptibility locus on chromosome 16p13 (maximum LOD score of 4.2, P=5 x 10(-6)). The GRIN2A (glutamate receptor, ionotropic, N-methyl D-aspartate 2A) gene that encodes the N-methyl D-aspartate receptor subunit 2A (NMDA2A) maps to this region of linkage. As this is also a good functional candidate gene for ADHD, we undertook family-based association analysis in a sample of 238 families. We found significant evidence of association with a GRIN2A exon 5 polymorphism (chi(2)=5.7, P=0.01). Our data suggest that genetic variation in GRIN2A may confer increased risk for ADHD and that this, at least in part, might be responsible for the linkage result on 16p reported by Smalley et al. We conclude that replication is required and that further work examining for association of GRIN2A polymorphisms with ADHD is warranted.
Collapse
Affiliation(s)
- D Turic
- Department of Psychological Medicine, University of Wales College of Medicine, Cardiff, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Affiliation(s)
- E J Speel
- Department of Molecular Cell Biology and Genetics, University of Limburg, Maastricht, The Netherlands
| | | | | | | | | |
Collapse
|
41
|
Gosden JR, Lawson D. Multiple sequential oligonucleotide primed in situ DNA syntheses (MULTI-PRINS). Methods Mol Biol 2003; 71:39-44. [PMID: 8959688 DOI: 10.1385/0-89603-395-3:39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J R Gosden
- Human Genetics Unit, Western General Hospital, Edinburgh, Scotland
| | | |
Collapse
|
42
|
Speel EJ, Lawson D, Ramaekers FC, Gosden JR, Hopman AH. Combined immunocytochemistry and PRINS DNA synthesis for simultaneous detection of phenotypic and genomic parameters in cells. Methods Mol Biol 2003; 71:53-9. [PMID: 8959690 DOI: 10.1385/0-89603-395-3:53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- E J Speel
- Department of Molecular Cell Biology and Genetics, University of Limburg, Maastricht, The Netherlands
| | | | | | | | | |
Collapse
|
43
|
Affiliation(s)
- J R Gosden
- Human Genetics Unit, Western General Hospital, Edinburgh, Scotland
| | | |
Collapse
|
44
|
Speel EJ, Lawson D, Ramaekers FC, Gosden JR, Hopman AH. Bright-field microscopic detection of oligonucleotide PRINS-labeled DNA in chromosome preparations. Methods Mol Biol 2003; 71:13-22. [PMID: 8959685 DOI: 10.1385/0-89603-395-3:13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- E J Speel
- Department of Molecular Cell Biology and Genetics, Univerity of Limburg, Maastricht, The Netherlands
| | | | | | | | | |
Collapse
|
45
|
Affiliation(s)
- J Gosden
- Human Genetics Unit, Western General Hospital, Edinburgh, Scotland
| | | | | |
Collapse
|
46
|
Gosden JR, Lawson D. Oligonucleotide primed in situ DNA synthesis (PRINS). An alternative to in situ hybridization for gene mapping and the investigation of genome organization. Methods Mol Biol 2003; 29:323-33. [PMID: 8032414 DOI: 10.1385/0-89603-289-2:323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- J R Gosden
- Human Genetics Unit, Western General Hospital, Edinburgh, Scotland
| | | |
Collapse
|
47
|
|
48
|
|
49
|
Cannon KE, Nalwalk JW, Stadel R, Ge P, Lawson D, Silos-Santiago I, Hough LB. Activation of spinal histamine H3 receptors inhibits mechanical nociception. Eur J Pharmacol 2003; 470:139-47. [PMID: 12798951 DOI: 10.1016/s0014-2999(03)01737-0] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Previous studies have suggested a possible pain-modulatory role for histamine H(3) receptors, but the localization of these receptors and nature of this modulation is not clear. In order to explore the role of spinal histamine H(3) receptors in the inhibition of nociception, the effects of systemically (subcutaneous, s.c.) and intrathecally (i.t.) administered histamine H(3) receptor agonists were studied in rats and mice. Immepip (5 mg/kg, s.c.) produced robust antinociception in rats on a mechanical (tail pinch) test but did not alter nociceptive responses on a thermal (tail flick) test. In contrast, this treatment in mice (immepip, 5 and 30 mg/kg, s.c.) did not change either mechanically or thermally evoked nociceptive responses. When administered directly into the spinal subarachnoid space, immepip (15-50 microg, i.t.) and R-alpha-methylhistamine (50 microg, i.t.) had no effect in rats on the tail flick and hot plate tests, but produced a dose- and time-dependent inhibition (90-100%) of nociceptive responses on the tail pinch test. This attenuation was blocked by administration of thioperamide (10 mg/kg, s.c.), a histamine H(3) receptor antagonist. Intrathecally administered thioperamide also reversed antinociceptive responses induced by systemically administered immepip, which demonstrates a spinal site of action for the histamine H(3) receptor agonist. In addition, intrathecally administered immepip (25 microg) produced maximal antinociception on the tail pinch test in wild type, but not in histamine H(3) receptor knockout (H(3)KO) mice. These findings demonstrate an antinociceptive role for spinal histamine H(3) receptors. Further studies are needed to confirm the existence of modality-specific (i.e. mechanical vs. thermal) inhibition of nociception by these receptors, and to assess the efficacy of spinally delivered histamine H(3) receptor agonists for the treatment for pain.
Collapse
Affiliation(s)
- Keri E Cannon
- Center for Neuropharmacology and Neuroscience, Albany Medical College MC-136, 47 New Scotland Ave., Albany, NY 12206, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
|